東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ subject:"Fraud- United States." ]

切換: 標籤 | MARC模式 | ISBD

Bad blood : = secrets and lies in a ...

Theranos (Firm)

FindBook

Google Book

Amazon

博客來

Bad blood : = secrets and lies in a Silicon Valley startup /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Bad blood :/ John Carreyrou.
其他題名:	secrets and lies in a Silicon Valley startup /
作者:	Carreyrou, John.
出版者:	New York :Alfred A. Knopf, : c2018.,
面頁冊數:	x, 339 p. ;24 cm.
標題:	Hematologic equipment industry - United States. -
ISBN:	9781524731656

Bad blood : = secrets and lies in a Silicon Valley startup /
Carreyrou, John.

Bad blood :secrets and lies in a Silicon Valley startup /John Carreyrou. - New York :Alfred A. Knopf,c2018. - x, 339 p. ;24 cm.

Includes bibliographical references (p. [305]-324) and index.

"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--

ISBN: 9781524731656

LCCN: 2018000263Subjects--Corporate Names:

3359992
Theranos (Firm)
--History.Subjects--Topical Terms:

3359993
Hematologic equipment industry
--United States.

LC Class. No.: HD9995.H423 / U627 2018

Dewey Class. No.: 338.7/681761

Bad blood : = secrets and lies in a Silicon Valley startup /
LDR:03583cam a2200229 a 4500 001 2149948
005 20190531153342.0
008 190320s2018 nyu b 001 0 eng
010 $a 2018000263
020 $a 9781524731656
020 $a 9781524711481 $q (pbk.) : $c US27.95
020 $a 9781524731663 $q (ebk.)
040 $a DLC $b eng $c DLC
042 $a pcc
043 $a n-us---
050 0 0 $a HD9995.H423 $b U627 2018
082 0 0 $a 338.7/681761 $2 23
100 1 $a Carreyrou, John. $3 3359991
245 1 0 $a Bad blood : $b secrets and lies in a Silicon Valley startup / $c John Carreyrou.
260 # $a New York : $b Alfred A. Knopf, $c c2018.
300 $a x, 339 p. ; $c 24 cm.
504 $a Includes bibliographical references (p. [305]-324) and index.
520 # $a "The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- $c Provided by publisher.
520 # $a "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- $c Provided by publisher.
610 2 0 $a Theranos (Firm) $x History. $3 3359992
650 # 0 $a Hematologic equipment industry $z United States. $3 3359993
650 # 0 $a Fraud $z United States. $3 656172